Experts say the chaos of last month’s CrowdStrike outage is likely to spark a flurry of litigation both overseas and at home, including class actions, but lawyers bringing the claims will face significant hurdles.
Dutch paint company AkzoNobel has lost a mid-trial bid to inspect instructions given by Allen & Overy to experts who tested its allegedly unsuitable protective coating used on pipework on the $45 billion Ichthys natural gas project.
A judge has rejected arguments that Virgin Australia waived legal professional privilege over advice from Herbert Smith Freehills by claiming in a class action defence that it had a reasonable belief that statements in a prospectus for a $324 million capital raising were not misleading.
The French association representing wine producers from Champagne has discontinued its lawsuit against an Australian retailer after it agreed to only use seed extract from the Champagne region of France.
Law firm Johnson Winter Slattery has recruited energy and resources specialist Nick Thorne for the firm’s Brisbance office, an appointment that represents a reunion for a former Corrs Chambers Westgarth trio.
Lawyers are allowed to take a cut from a class action settlement or judgment under a so-called solicitors’ common fund order, the Full Federal Court has ruled, saying they are a permissive use of the court’s power.
Google has slammed Fortnite game maker Epic Games’ landmark competition case against it as “contrary to commercial reality”, saying its competition with rival tech giant Apple means it is no monopolist.
In a landmark competition case, Apple has told the Federal Court that Epic Games and other developers should not be allowed to “freeride” on the resources and user base the tech giant has “spent many billions” to develop.
Five years after it was first hit with a competition case by Dialogue Consulting, Meta has filed a cross-claim against the Melbourne social media company, alleging it collects and stores Instagram user login credentials and instructs clients to provide inaccurate information to the platform.
A judge has rejected Samsung Bioepis’ bid to discover research and development documents from Pfizer as it seeks to invalidate the drug giant’s patent for its blockbuster autoimmune drug Enbrel, agreeing with Pfizer that it may be “no more than an exercise in fishing”.